Recent research by Xie and colleagues [10] suggests that overexpression of P21 is associated with a poor prognosis in patients with non-small-cell lung cancer, while the loss of P21 protein expression could be a significant predictor of disease progression in patients with pancreatic cancer [11]. This evidence concerns the gene CDKN1A and non-small cell lung carcinoma.